
Aerpio Pharmaceuticals, Inc. Revenue 2011-2026 | ARPO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 15 M | - | 20.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.2 M | 15 M | 17.6 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Precigen
PGEN
|
9.68 M | $ 3.1 | -0.96 % | $ 758 M | ||
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | ||
|
I-Mab
IMAB
|
88 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | ||
|
Ascendis Pharma A/S
ASND
|
720 M | $ 220.9 | 2.49 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 19.57 | 1.77 % | $ 915 M | ||
|
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.33 | 0.76 % | $ 339 M | ||
|
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | ||
|
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
32.2 M | - | - | $ 3.74 B | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | ||
|
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
882 K | $ 8.31 | 1.59 % | $ 111 M | ||
|
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 47.09 | 1.42 % | $ 4.23 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.53 | 5.1 % | $ 868 M | ||
|
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | ||
|
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | ||
|
CytomX Therapeutics
CTMX
|
76.2 M | $ 4.22 | -0.47 % | $ 582 M | ||
|
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
43 K | - | -5.98 % | $ 34.1 M |